US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gemphire Therapeutics

0.3000

+0.0000

Volume:- -

Turnover:- -

Market Cap:4.46M

PE:-0.31

High:0.3000

Open:0.3000

Low:0.3000

Close:0.3000

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Gemphire Therapeutics

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.gemphire.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease. Its product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. The company was founded in 2008 and is headquartered in Northville, Michigan.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GEMP/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GEMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GEMP\",,,,,undefined,":{"symbol":"GEMP","market":"US","secType":"STK","nameCN":"Gemphire Therapeutics","latestPrice":0.3,"timestamp":1577739600000,"preClose":0.3,"halted":8,"volume":0,"delay":0,"floatShares":10283980,"shares":14872411,"eps":-0.967778,"marketStatus":"Pre-Mkt","change":0,"latestTime":"05-05 07:11:20 EDT","open":0.3,"high":0.3,"low":0.3,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.967778,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746451800000},"marketStatusCode":1,"symbolChange":{"newSymbol":"NRBO","executeDate":"2019-12-31"},"adr":0,"adrRate":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":0.3,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GEMP\",,,,,undefined,":{"symbol":"GEMP","floatShares":10283980,"roa":"-44.90%","roe":"-280.97%","lyrEps":-1.712137,"shares":14872411,"dividePrice":0,"high":0.3,"amplitude":0,"preClose":0.3,"low":0.3,"week52Low":0.238,"pbRate":"2.27","week52High":1.485,"institutionHeld":0,"latestPrice":0.3,"eps":-0.967778,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.967778,"open":0.3},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.gemphire.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0293},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0583},{"period":"6month","weight":-0.0075},{"period":"1year","weight":0.1222},{"period":"ytd","weight":-0.033}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease. Its product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. The company was founded in 2008 and is headquartered in Northville, Michigan.","exchange":"NASDAQ","name":"Gemphire Therapeutics","nameEN":"Gemphire Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"GEMP\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GEMP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-12-31","symbol":"GEMP","oldSymbol":"GEMP","newSymbol":"NRBO","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1577768400000},{"market":"US","date":"2019-12-31","symbol":"GEMP","type":"split","dateTimestamp":1577768400000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2019-08-09","symbol":"GEMP","fiscalQuarterEnding":"2019/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1565323200000,"reportTimeType":"","actualEps":-0.2},{"market":"US","date":"2019-05-09","symbol":"GEMP","fiscalQuarterEnding":"2019/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1557374400000,"reportTimeType":"","actualEps":-0.27},{"market":"US","date":"2019-03-15","symbol":"GEMP","fiscalQuarterEnding":"2018/12","expectedEps":-0.39,"name":null,"time":"","type":"earning","dateTimestamp":1552622400000,"reportTimeType":"","actualEps":-0.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GEMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GEMP\",market:\"US\",delay:false,,,undefined,":{}}}